Skip to main content

Precision Oncology

Precision Oncology

Due to the heterogeneous nature of tumors, molecular profiling is crucial to our understanding of how genomics plays a role in the cause or development of an individual cancer. Such tumor profiles can subsequently be applied to exclusively tailor cancer therapies to directly target a causative mutation for a malignancy, ultimately achieving a personalized and precise approach to cancer treatment. This approach is termed precision oncology.

Precision oncology has made progress in leaps and bounds in recent years and is currently at the heart of revolutionizing cancer research. As this research continues to develop and evolve, the enhanced use of precision oncology in cancer treatment ultimately aims to improve prognosis and outcomes for patients.

We are therefore very proud to present a new cross-journal thematic series focusing on precision oncology. This cross-journal thematic series of original research and review articles gathers the latest research on precision oncology. It focuses on how precision oncology has shaped advances in the impact of non-coding RNAs in epigenetics and cancer, immunotherapy and tumor biology, and the clinical significance of various therapies in a range of cancers. 
 

Participating journals

Page 2 of 2

  1. Breast cancer patients who have not previously attended mammography screening may be more likely to discontinue adjuvant hormone therapy and therefore have a worse disease prognosis.

    Authors: Wei He, Louise Eriksson, Sven Törnberg, Fredrik Strand, Per Hall and Kamila Czene
    Citation: BMC Medicine 2019 17:24
    Content type: Research article Published on:

  2. Circulating tumor cells (CTCs) have been described as a population of cells that may seed metastasis, which is a reliable target for the prevention of metastases in lung cancer patients at the early stage. The...

    Authors: Zujun Que, Bin Luo, Zhiyi Zhou, Changsheng Dong, Yi Jiang, Lin Wang, Qihui Shi and Jianhui Tian
    Citation: Cancer Cell International 2019 19:21
    Content type: Primary research Published on:

  3. Although low-grade serous ovarian cancer (LGSC) is rare, case-fatality rates are high as most patients present with advanced disease and current cytotoxic therapies are not overly effective. Recognizing that t...

    Authors: Marta Llaurado Fernandez, Amy Dawson, Joshua Hoenisch, Hannah Kim, Sylvia Bamford, Clara Salamanca, Gabriel DiMattia, Trevor Shepherd, Mattia Cremona, Bryan Hennessy, Shawn Anderson, Stanislav Volik, Colin C. Collins, David G. Huntsman and Mark S. Carey
    Citation: Cancer Cell International 2019 19:10
    Content type: Primary research Published on:

  4. Chronic diseases such as chagasic megaesophagus (secondary to Chagas’ disease) have been suggested as etiological factors for esophageal squamous cell carcinoma; however, the molecular mechanisms involved are ...

    Authors: Fernanda Franco Munari, Adriana Cruvinel-Carloni, Croider Franco Lacerda, Antônio Talvane Torres de Oliveira, Cristovam Scapulatempo-Neto, Sandra Regina Morini da Silva, Eduardo Crema, Sheila Jorge Adad, Maria Aparecida Marchesan Rodrigues, Maria Aparecida Coelho Arruda Henry, Denise Peixoto Guimarães, Adhemar Longatto-Filho and Rui Manuel Reis
    Citation: Infectious Agents and Cancer 2018 13:43
    Content type: Research article Published on:

  6. Helicobacter pylori (H. pylori)-induced gastric cancer is an intricate progression of immune response against H. pylori infection. IL-16, TGF-β1 and TLR4 pathways were the mediators involved in the immune respons...

    Authors: Bangshun He, Tao Xu, Bei Pan, Yuqin Pan, Xuhong Wang, Jingwu Dong, Huiling Sun, Xueni Xu, Xiangxiang Liu and Shukui Wang
    Citation: Cancer Cell International 2018 18:191
    Content type: Primary research Published on: